Tranexamic acid improves survival outcomes in patients with bleeding due to trauma or childbirth when administered within three hours of the onset of the bleeding.
Highlights:
- Major bleeds can be fatal in the immediate period if not addressed immediately
- Tranexamic acid improves survival outcomes in patients suffering from post-trauma and postpartum bleeding, especially when administered early
- The survival benefits reduce by 10% with a delay of every 15 minutes, and are absent after three hours
Scientists studied the data obtained from two published clinical trials (CRASH-2 and WOMAN) to understand the survival benefits and the consequences of delaying treatment with anti-fibrinolytic drugs. Clinical trials assessed more than 40138 patients with acute severe bleeding due to trauma or following childbirth. The scientists found that
- Forty percent of deaths in the studies were due to bleeding. Around 63 percent of these deaths occurred within 12 hours of the onset of bleeding. In fact, deaths following childbirth most commonly occurred 2 to 3 hours after delivery.
- The administration of tranexamic acid increased survival following the bleeding. When the treatment was administered immediately after bleeding, the survival improved by 70%.
- The benefits of survival reduced when the treatment was delayed. Even a small delay reduced its effectiveness. The effectiveness reduced by 10% for a delay of every 15 minutes till 3 hours following the onset of bleeding. Beyond 3 hours, no benefit was noted.
- Tranexamic acid did not appear to be associated with significant serious adverse effects. It did not increase the chances of adverse events like heart attack, stroke, pulmonary embolism and deep vein thrombosis due to intravascular clot formation.
Reference:
- Gayet-Ageron et al. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. The LancetDOI: http://dx.doi.org/10.1016/S0140-6736(17)32455-8
Source-Medindia